Brett Arends described the U.S. stock market as "one of the most dangerous in the world (http://www.marketwatch.com/story/why-the-us-market-is-one-of-the-most-dangerous-in-the-world-2015-02-18)," based on the research of Wellershoff & Partners, and suggested it may be a good idea to diversify with some international or emerging markets funds.
A.M. Best has affirmed the financial strength rating of A
(Excellent) and the issuer credit rating of “a” of RBC Life Insurance
Company (RBC Life) (Mississauga, Ontario). The outlook for both
ratings is stable.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that it will report its
financial results for the fourth quarter and year ended December 31,
2014 on Thursday, February 26, 2015, after the U.S. financial markets
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization of
novel protein therapeutics for cancer and rare diseases, today announced
that new preliminary data from the DART study, an ongoing phase 2
clinical trial of dalantercept in patients with advanced renal cell
carcinoma (RCC) will be presented at the American Society of Clinical
Oncology (ASCO) 2015 Genitourinary Cancers Symposium in Orlando,
Accuride Corporation (NYSE: ACW), a leading supplier of components to
the North American commercial vehicle industry, today announced that it
will host a conference call to discuss its financial and operational
results for the Fourth Quarter and Full-Year Fiscal 2014 on Tuesday,
March 3, 2015, beginning at 9:00 a.m. CST.
ACE Group announced today leadership appointments for its ACE Private
Risk Services business that will be effective when the acquisition of
the U.S. high net worth personal lines insurance business of Fireman’s
Fund is completed.
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has expanded the existing indication for
REVLIMID ® (lenalidomide) in combination with dexamethasone to
include patients newly diagnosed with multiple myeloma (NDMM). REVLIMID
plus dexamethasone was previously approved in June 2006 for use in
multiple myeloma patients who have received at least one prior therapy.
FRANKFURT-- Adidas AG said Thursday it was conducting a search to replace its longtime chief executive, as the German sportswear maker struggles with a series of profit warnings and investor pressure for change at the top.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.